Skip to main content

Table 1 Baseline clinical characteristics of the patients with chronic heart failure who underwent cardiopulmonary exercise testing (n = 73)

From: Left atrial dysfunction can independently predict exercise capacity in patients with chronic heart failure who use beta-blockers

Variables

Overall population (n = 73)

VO2max ≥ 16 mL/kg/min (n = 38)

VO2max < 16 mL/kg/min (n = 35)

P value for comparison

P value for correlation with linear VO2max

Demographics

     

Age, years

61 ± 10

57 ± 10

65 ± 9

0.001**

 < 0.0001***

Male

57 (78%)

34 (90%)

23 (66%)

0.014*

0.004**

Height, cm

166 ± 7

168 ± 7

164 ± 7

0.001**

0.022*

Weight, kg

68 ± 11

69 ± 12

67 ± 10

0.569

0.530

BMI, kg/m2

25 ± 4

24 ± 3

25 ± 4

0.249

0.414

BSA, m2

1.8 ± 0.2

1.8 ± 0.2

1.7 ± 0.2

0.270

0.303

Comorbidities and etiology

     

Coronary heart disease

43 (59%)

26 (68%)

17 (49%)

0.085

0.349

Myocardial infarction

20 (27%)

12 (32%)

8 (23%)

0.404

0.595

Dilated cardiomyopathy

19 (26%)

9 (24%)

10 (29%)

0.634

0.491

Hypertrophic cardiomyopathy

2 (3%)

1 (3%)

1 (3%)

0.953

0.485

NVM

2 (3%)

1 (3%)

1 (3%)

0.953

0.939

Moderate mitral regurgitation

16 (22%)

6 (16%)

10 (26%)

0.187

0.171

Diabetes

30 (41%)

16 (42%)

14 (40%)

0.860

0.999

Hypertension

32 (44%)

15 (39%)

17 (49%)

0.434

0.062

Hyperlipidemia

26 (36%)

13 (34%)

13 (37%)

0.794

0.752

Hyperuricemia

26 (36%)

11 (29%)

15 (43%)

0.215

0.036*

CKD (compensation stage)

7 (10%)

3 (8%)

4 (11%)

0.608

0.291

COPD

4 (5%)

3 (8%)

1 (3%)

0.360

0.670

Laboratory variables

     

NT-proBNP, pg/mL

892 ± 1417

516 ± 664

1301 ± 1855

 < 0.0001***

0.004**

Hemoglobin, g/L

145 ± 15

149 ± 12

139 ± 16

0.003**

0.003**

Creatinine, mg/dL

95 ± 23

98 ± 23

91 ± 24

0.695

0.371

Sodium, mEq/L

139 ± 6

139 ± 7

140 ± 3

0.636

0.055

GFR, mL/min/1.73 m2

73 ± 17

76 ± 18

69 ± 16

0.082

0.044*

Glucose, mmol/L

7 ± 2

6 ± 2

7 ± 2

0.947

0.720

Triglycerides, mmol/L

1.5 ± 1.4

1.7 ± 1.8

1.4 ± 0.6

0.800

0.140

Cholesterol, mmol/L

4.2 ± 1.5

4.3 ± 1.8

4.1 ± 1.1

0.774

0.322

HDL, mmol/L

1.21 ± 0.28

1.21 ± 0.25

1.2 ± 0.3

0.995

0.682

nHDL, mmol/L

3.0 ± 1.5

3.1 ± 1.8

2.8 ± 1.1

0.770

0.265

LDL, mmol/L

2.4 ± 0.9

2.4 ± 0.8

2.4 ± 1.0

0.943

0.748

Oral drugs

     

Inhibitors of RAS

48 (66%)

28 (74%)

20 (57%)

0.137

0.078

Spironolactone

47 (64%)

19 (50%)

28 (80%)

0.007**

0.003**

ARNI

15 (21%)

7 (18%)

8 (23%)

0.639

0.487

CCB

7 (10%)

2 (5%)

5 (14%)

0.204

0.411

P2Y12 receptor antagonist

29 (40%)

17 (45%)

12 (34%)

0.362

0.510

Statin

53 (73%)

26 (68%)

27 (77%)

0.404

0.390

Trimetazidine

7 (10%)

3 (8%)

4 (11%)

0.608

0.308

Aspirin

21 (29%)

10 (26%)

11 (31%)

0.630

0.878

Warfarin

10 (14%)

4 (11%)

6 (17%)

0.411

0.445

  1. * P < 0.05, ** P < 0.01, *** P < 0.001
  2. Data are presented as the mean ± standard deviation or the n (%). BMI, body mass index; BSA, body surface area; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; GFR, glomerular filtration rate; HDL, high-density lipoprotein. HR, heart rate; LDL, low-density lipoprotein; NT-proBNP, N-terminal pro-brain natriuretic peptide; nHDL, nonhigh-density lipoprotein; NVM, noncompaction of ventricular myocardium; RAS renin-angiotensin system; ARNI, angiotensin receptor neprilysin inhibitor; CCB, calcium channel blocker
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us